HighVista Strategies’s Kronos Bio KRON Stock Holding History

HighVista Strategies’s Portfolio KRON Stock Details KRON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-26,944	Closed	-$789K	–	130
2021 Q1	$789K	Buy	+26,944	New	+$789K	0.59%	29

Other funds holding KRON

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VVA

Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

HighVista Strategies's KRON Position: Q2 2021 in Review

HighVista Strategies sold out of Kronos Bio (KRON) in Q2 2021, closing a stake of 26,944 shares — an estimated $789K sold.

HighVista Strategies first reported a position in KRON in Q1 2021 and held it in 1 quarter. The position peaked at $789K in Q1 2021. 77 funds tracked by Wall St. Rank hold KRON as of Q2 2021.

HighVista Strategies reported no remaining Kronos Bio position as of Q2 2021 after selling out during the quarter.
HighVista Strategies sold 26,944 Kronos Bio shares in Q2 2021, an estimated $789K.
HighVista Strategies first reported a position in Kronos Bio in Q1 2021 and held it in 1 quarter.
HighVista Strategies's Kronos Bio position peaked at $789K in Q1 2021.
77 funds tracked by Wall St. Rank held Kronos Bio as of Q2 2021.

Based on HighVista Strategies's 13F filing for Q2 2021, filed 16 Aug 2021.